3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
4
Terminated
2
Completed
2
Unknown
1
Active not recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
16
Recurrence
3
Neoplasms, Plasma Cell
2
Renal Insufficiency
1
Paraproteinemias
1
Neoplasms by Histologic Type
1
Neoplasms
1
Immunoglobulin Light-chain Amyloidosis
1
Hypoxia
1
High Grade Squamous Intra-epithelial Lesion (HSIL)
1
Hematologic Diseases
1
Disease Progression
1
Blood Protein Disorders
1
Amyloidosis
1
Interventions
Cyclophosphamide
4
Dexamethasone
3
sargramostim
2
Bortezomib
2
pomalidomide
1
isatuximab
1
elotuzumab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
auricularum
1
Thalidomide
1
Technetium Tc 99m Pyrophosphate
1
Technetium
1
Registries
1
Radiotherapy
1
Pharmacogenomic Testing
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Lenalidomide
1
Ketamine
1
Filgrastim
1
Carboplatin
1
Calcium Dobesilate
1
Amifostine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Immunoglobulin Light-chain Amyloidosis
×
pomalidomide
×
Clear all
NCT05066607
2024-03-06
IsAMYP
Intergroupe Francophone du Myelome
Phase 2
Unknown
46 enrolled